Cogent NDA for Bezuclastinib Advances Under FDA RTOR
WALTHAM, Mass. & BOULDER, Colo., January 20, 2026 — Cogent Biosciences announced that the U.S. Food and Drug Administration...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
WALTHAM, Mass. & BOULDER, Colo., January 20, 2026 — Cogent Biosciences announced that the U.S. Food and Drug Administration...
EAST HANOVER, N.J. — December 12, 2025 — Novartis, a global innovative medicines company, has officially broken ground on...
